BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG ...

BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another ...

On October 27, 2025, BridgeBio Pharma announced positive topline results from its pivotal Phase 3 FORTIFY study for BBP-418 in individuals with limb-girdle muscular dystrophy type 2I/R9, achieving all ...

Bridgebio Pharma says it will seek U.S. approval of BBP-418 for LGMD2i after Phase 3 trial data showed a range of benefits ...

The $12.5 billion acquisition of Avidity Biosciences Inc. by Novartis AG strengthens the company’s neuroscience pipeline and marks the second biggest deal that’s been announced this year. San ...

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy ...

BridgeBio Pharma ( ($BBIO) ) has shared an announcement. On October 27, 2025, BridgeBio Pharma announced positive results from its Phase 3 FORTIFY ...

Shares of BridgeBio Pharma rose more than 15% to $62.52 in early trading, after the company reported positive top-line ...

BridgeBio Pharma (NASDAQ:BBIO) shares surged 15% on Monday after the company announced highly positive Phase 3 results for ...

BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...

Shares of BridgeBio Pharma rose after the company reported positive data in the phase three study of its treatment of limb-girdle muscular dystrophy. The stock rose 10% to $59.74 in premarket trading ...

All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile ...